SCHEMBL574414

SCHEMBL574414

CC(N)(CCC(N)=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.54
ARG1 P05089 1/20 0.48
ARG2 P78540 1/20 0.48
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 3/20 0.38
NOS2 P35228 5/20 0.38
NOS1 P29475 3/20 0.38
NOS3 P29474 1/20 0.38
ALOX15 P16050 2/20 0.35
PMP22 Q01453 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
EGFR P00533 1/20 0.35
FYN P06241 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL159588 1.00 GGT1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL164555 1.00 GGT1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL200536 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL200537 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL473835 0.83 ALDH1A1 (0.56) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL8687592 0.82 GGT1 (0.65) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL434488 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL10780975 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
Water SCHEMBL10780977 0.81 ALDH1A1 (0.54) GGT1ARG1ARG2ALDH1A1KMT2A
SCHEMBL3419878 0.80 ARG1 (0.38) GGT1ARG1ARG2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12589087-B2 Enantiomer selective action on neurotransmission THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-03-31 US claimed
US-20240115539-A1 ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-04-11 US claimed
EP-4319735-A1 ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION The Board of Trustees of the Leland Stanford Junior University (US) 2024-02-14 EP claimed
CN-117425472-A Enantioselective action on neurotransmission 小利兰·斯坦福大学托管委员会 2024-01-19 CN claimed
WO-2022216543-A1 ENANTIOMER SELECTIVE ACTION ON NEUROTRANSMISSION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-10-13 WO claimed
US-20160318987-A1 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2016-11-03 US claimed
EP-3080153-A2 PROTEASE RESISTANT PEPTIDES Medimmune Limited (GB) 2016-10-19 EP claimed
WO-2015086686-A2 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2015-06-18 WO claimed
US-20120264685-A1 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2012-10-18 US claimed
EP-2491054-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST Cadila Healthcare Limited (IN) 2012-08-29 EP claimed
WO-2011048614-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2011-04-28 WO claimed
WO-2026107423-A1 ORAL PEPTIDES AND USES THEREOF FOR WEIGHT LOSS, WEIGHT MAINTENANCE, AND MANAGEMENT OF METABOLIC CONDITIONS METSERA, INC. (US) 2026-05-21 WO disclosed
US-12630600-B2 GLP-1 and glucagon dual agonist peptides with improved biological stability MEDIMMUNE LIMITED (GB) 2026-05-19 US disclosed
EP-4736944-A2 POLYPEPTIDES AND USES THEREOF MedImmune Limited (GB) 2026-05-06 EP disclosed
US-12589087-B2 Enantiomer selective action on neurotransmission THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-03-31 US disclosed
EP-1209234-A1 STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2002-05-29 EP disclosed
EP-1015494-A4 CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME KOENTGEN FRANK (AU) 2001-12-12 EP disclosed
EP-1015494-A1 CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME Amrad Operations Pty.,Ltd. (AU) 2000-07-05 EP disclosed
WO-1999015563-A1 CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1999-04-01 WO disclosed
WO-1999014243-A1 IMMUNOINTERACTIVE MOLECULES AND USES THEREFOR CONE ROBERT EDWARD (US) 1999-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630600-B2 GLP-1 and glucagon dual agonist peptides with improved biological stability GLP1R, GIPR, GCGR GGT1 1915/4885ARG1 1538/4885ARG2 2286/4885
US-20120264685-A1 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST GIPR, GLP1R, DPP4 GGT1 150/4885ARG1 501/4885ARG2 704/4885
US-12589087-B2 Enantiomer selective action on neurotransmission SLC1A2, GLUL, SLC6A13 GGT1 445/4885ARG1 1491/4885ARG2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.